Results 1 to 10 of about 623,160 (229)
Antinephrin autoantibodies: rethinking the pathogenesis of minimal change disease. [PDF]
Ren FailXue C, Zhou C, Mao Z.
europepmc +2 more sources
Secondary minimal change disease [PDF]
Nephrology Dialysis Transplantation, 2003 The great majority of patients identified as having a 'minimal change lesion' accompanying the nephrotic syndrome have a primary or 'idiopathic' disorder. Nevertheless, it is quite apparent that a similar or identical lesion can appear consequent to a growing number of underlying diseases; it is then known as 'secondary minimal change disease'.
openaire +2 more sources
Immune Characteristics of IgA Nephropathy With Minimal Change Disease
Frontiers in Pharmacology, 2021 Background: IgA nephropathy (IgAN) has a high degree of heterogeneity in clinical and pathological features. Among all subsets of IgAN, the pathogenesis of IgAN with minimal change disease (MCD-IgAN) remained controversial.Methods: We analyzed the ...
Huixian Li +12 more
doaj +1 more source
Clinical trials in minimal change disease [PDF]
Nephrology Dialysis Transplantation, 2017 Minimal change disease (MCD) is a pathological condition characterized by subtle glomerular lesions causing massive and reversible proteinuria that is usually steroid sensitive. Recurrence of symptoms of active disease following successful treatment (including proteinuria, oedema and oliguria) and steroid toxicity requires the use of other drugs to ...
Pietro, Ravani +3 more
openaire +2 more sources
Management of Adult Minimal Change Disease [PDF]
Clinical Journal of the American Society of Nephrology, 2019 Minimal change disease is responsible for idiopathic nephrotic syndrome in >75% of children and up to 30% of adults ([1][1]–[5][2]). Although secondary causes of minimal change disease ( i.e.
Stephen M, Korbet, William L, Whittier
openaire +2 more sources
Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy
Clinics and Practice, 2021 Lupus podocytopathy (LP) is an uncommon manifestation of systemic lupus erythematosus (SLE) and is not included in the classification of lupus nephritis.
Rasha Aly +3 more
doaj +1 more source
Minimal-change disease secondary to etanercept [PDF]
Clinical Kidney Journal, 2012 Etanercept is a soluble tumor necrosis factor alpha (TNFα) receptor which is widely used in the treatment of rheumatoid arthritis, psoriasis and other autoimmune inflammatory disorders. It is known for its relative lack of nephrotoxicity; however, there are reports on the development of nephrotic syndrome associated with the treatment with TNFα ...
Koya, Mariko +2 more
openaire +2 more sources
Canadian Journal of Kidney Health and Disease, 2021 Rationale: While severe complications are generally uncommon with novel coronavirus disease 2019 (COVID-19) vaccine, there has been a steady increase in the number of patients presenting with nephrotic syndrome and acute kidney injury after the ...
Jessica Hanna +2 more
doaj +1 more source
Kidney Research and Clinical Practice, 2012 Background: Few clinical trials have examined the replacement of steroids with other immunosuppressive drugs as a primary treatment modality for minimal change disease (MCD) in adults.
Yong Chul Kim +7 more
doaj +1 more source
IgA Nephropathy with Minimal Change Disease [PDF]
Clinical Journal of the American Society of Nephrology, 2014 Patients with IgA nephropathy typically present with hematuria and subnephrotic proteinuria. Nephrotic syndrome is uncommon in IgA nephropathy, and when present, it is usually associated with severe histologic features, such as endocapillary proliferation, segmental sclerosis, and crescent formation.
Leal C, Herlitz +5 more
openaire +2 more sources